Scopus BioPharma Inc. Common Stock
SCPS
SCPS was delisted on the 16th of December, 2022.
21 hedge funds and large institutions have $4.71M invested in Scopus BioPharma Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
313% more capital invested
Capital invested by funds: $1.14M → $4.71M (+$3.57M)
50% more funds holding
Funds holding: 14 → 21 (+7)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$6.37M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.1M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$200K |
| 4 |
Morgan Stanley
New York
|
+$130K |
| 5 |
Two Sigma Investments
New York
|
+$92.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$226K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$51.5K |
| 3 |
First Manhattan
New York
|
-$6.06K |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$1.44K |
SCPS Hedge Fund Activity: Q4 2021 in Review
21 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q4 2021, worth a combined $4.71M — up 313% from $1.14M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SCPS positions and 1 closed out — a net gain of 7 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $6.37M. The largest seller was Millennium Management, cutting an estimated $226K.
- 21 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q4 2021, up from 14 in Q3 2021.
- Funds reported $4.71M of Scopus BioPharma Inc. Common Stock stock for Q4 2021, up 313% quarter-over-quarter.
- 8 funds opened new Scopus BioPharma Inc. Common Stock positions in Q4 2021 and 1 closed out, a net change of +7 holders.
- The largest Scopus BioPharma Inc. Common Stock buyer in Q4 2021 was Armistice Capital, an estimated $6.37M added.
- The largest Scopus BioPharma Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $226K sold.
Based on aggregated 13F filings for Q4 2021.